Drug-induced Obesity, Metabolic Syndrome X, Obesity, Schizophrenia
Conditions
Keywords
Obesity, The Metabolic Syndrome/disturbances, Drug-induced adipositas, Schizophrenia, GLP-1 analogue, cerebral effects
Brief summary
To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic spectrum. The investigators will also examine possible associations between GLP-1 treatment and peripheral metabolic parameters such as change in body fat and HbA1c. Moreover, the GLP-1 analogue treatment will be associated with the effects/changes on cognition and subjective quality of life. Possible cerebral effects (pro-cognitive) of the GLP-1 analogue treatment will associated and correlated with changes in the brain, functional magnetic resonance imaging (fMRI).
Detailed description
The primary endpoint is weight loss after 3 months of treatment with the GLP-1 analogue exenatide (Bydureon®). Secondary endpoints comprise both physiological/metabolic parameters and cognitive measurements: * Metabolic endpoints include amongst others: changes in body fat (DEXA-scan) and changes of the HbA1c(average blood glucose levels), cholesterol and triglycerides. Moreover physiological effects will be examined eg possible effect on central/peripheral bloodpressure and heart rate. * Cerebral endpoints will be investigated via functional magnetic resonance imaging (fMRI); including potential neuroprotective effects of exenatide. The main focus is potential hippocampal volume changes and potential changes in cerebral blood flow. Functional MRI will provide this data and the images will be correlated to both cognitive tests and questionnaires. * Cognitive endpoints comprise potential improvements in cognition with focus on specific memory tests (BACS, DART and Rey's Complex Figure) and possible improvements in subjective quality of life (questionnaires).
Interventions
DRUGExenatide
Subcutaneum injection of exenatide once-weekly for 3 months
DRUGPlacebo
Subcutaneum injection of placebo once-weekly for 3 months
Sponsors
Bjorn H. Ebdrup
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18 - 65 years * Diagnosis of the schizophrenia spectrum (ICD-10: F20.x, F25.x)both in-patients and out-patients will be included * Current and unchanged treatment with at least one antipsychotic drug (FGA and/or SGA and/or depot treatment) * BMI ≥30 kg/m2 * HbA1c \< 6,5 %
Exclusion criteria
* Substance dependence (ICD-10: F1x.2 (apart from nicotine addiction F17.2)) * Diabetes or HbA1c ≥6.5% * Contraindications to MRI (metal implants, pacemakers, severe claustrophobia, ≥150 kg (max. bed weight in the MRI scanner)) * Previous head trauma with a loss of consciousness for more than 5 minutes * Pregnancy (screened by urine human chorionic gonadotropin (hCG),lactation or no acceptance to use effective contraception during the intervention period * Severe somatic disease, including inflammatory bowel disease and chronic ketoacidosis * Allergy to exenatide * Coercive measures according the Danish Law of Psychiatry * conditions that according to sponsor are not congruous with participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight loss | 3 months | The primary endpoint is weight loss after 3 months of treatment with a GLP-1 analogue. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effects of GLP-1-analogue treatment on body fat composition | 3 months | The investigators will explore potential effects of GLP-1 analogue treatment on different peripheral metabolic parameters: mainly changes in body fat composition (measured by DEXA-scan) and effects on HbA1c, triglycerides and cholesterol. |
Countries
Denmark
Outcome results
None listed